The FDA's decision to approve inotuzumab ozogamicin for patients with relapsed or refractory acute lymphoblastic leukemia could open up further uses for the drug. It is being tested as a first-line treatment in combination with chemotherapy. The decision could also stimulate research into other antibody–drug conjugates.
from Cancer via ola Kala on Inoreader http://ift.tt/2wuvjIa
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου